Does local adminstration of the drug granisetron influence facial skin sensitivity?

Effect of granisetron on facial skin sensitivity in healthy volunteers - Granosetron and facial skin sensitivity

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-000026-57-SE

Enrollment

Registered

2013-05-14

Start date

2013-07-19

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy and pain-free volunteers > 20 years of age, both sexes

Interventions

Trade Name: Kytril Pharmaceutical Form: Injection Pharmaceutical form of the placebo: Injection Route of administration of the placebo: Subcutaneous use Trade Name: Xylocain Pharmaceutical Form: Inje

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Good general health 2) Age 20-40 years Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 30 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range 0

Exclusion criteria

Exclusion criteria: 1) Facial pain 2) Systemic diseaases where pain is part of symptoms 3) Pregnancy or lactation 4) Use of analgesic drugs (e.g. paracatamol, NSAID) 48 hr before trial 5) Medication with other drugs that can influence pain perception (e.g. antidepressants, anxiolytics) 6) high blood pressure 7) previous allergy or side effects of granisetron or lidocaine.

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate the effect of granisetron on facial skin sensitivity;Secondary Objective: To investigate if there is any sex differences in the effect of granisteron ;Primary end point(s): Increase of sensory or pain thresholds;Timepoint(s) of evaluation of this end point: 5, 15, 30, 45 and 60 min	—

Secondary

Measure	Time frame
Secondary end point(s): 50% decrease of pain intensity to given stimuli (pin-prick, heat, cold);Timepoint(s) of evaluation of this end point: 5, 15, 30, 45 and 60 min	—

Countries

Sweden

Contacts

Public ContactDepartment of Dental medicine

Karolinska Institutet

malin.ernberg@ki.se46852488236

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026